Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.13-0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -13.4% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 46.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TRDA — officer change
Dated 2026-06-10
Annual board election held in a virtual-only format.
Why it matters: This data will assess the safety and efficacy of VX-670 for DM1. Positive results could enhance Entrada's partnership value.
Supportive ifVX-670 data shows big safety and effectiveness gains in DM1 patients.
Worry ifData shows serious safety issues or no effectiveness. This weakens the partnership's value.
Why it matters: These results are key to Entrada's growth strategy. Positive results could boost investor confidence.
Supportive ifCohort 1 and 2 study results are positive. They meet the main goals.
Worry ifStudy results are negative or do not meet primary endpoints.
Why it matters: Growth in the Duchenne franchise is vital for Entrada's overall performance. Strong growth signals market acceptance.
Supportive ifManagement reports strong growth or new partnerships in the Duchenne franchise.
Worry ifDuchenne franchise growth metrics show stagnation or decline.
Why it matters: This data will assess long-term safety and functional measures of ENTR-601-44. Positive results could enhance the drug's profile.
Supportive ifCohort 1 data shows it is safe. It also shows better function.
Worry ifData shows no improvement. There are no safety problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$299 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $660 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,475 loss on $10,000 · 64.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This data will show how well a higher dose of ENTR-601-44 works. Good results could support higher dose strategies.
Supportive ifCohort 2 data shows better safety. It also shows better outcomes than Cohort 1.
Worry ifCohort 2 data shows no improvement. There are no problems compared to Cohort 1.
Why it matters: This data will confirm the long-term safety and functional benefits of ENTR-601-44. It is crucial for the DMD franchise.
Supportive ifPositive data shows the drug is safe. It also helps improve function over time.
Worry ifNegative data raises concerns. It worries about the drug's long-term use.
Why it matters: Changes in dosing could impact the study's outcomes and regulatory path. Positive discussions may lead to a faster path to market.
Supportive ifFDA agrees to increase the planned starting dose for the ELEVATE-44-102 study.
Worry ifFDA does not approve the proposed changes to dosing.
Why it matters: This data will show how well the treatment works for Duchenne muscular dystrophy. Positive results could boost confidence in the pipeline.
Supportive ifCohort 1 data shows good safety and early benefits.
Worry ifCohort 1 data shows safety issues or no benefits.